Frontlight ResearchEarly access
Active, not recruitingEarly phase 1
Diclofenac as a KMO Inhibitor
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Catonsville, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 12 people, planned
- Started
- 31 Jul 2024
- Ended
- Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Diclofenac
- Placebo
- Record updated
- 27 March 2026
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Ages 21-65
- Meet DSM-5 diagnostic criteria for AUD of any severity (Mild, Moderate, or Severe)
Who cannot take part
- Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, and diuretics like furosemide and thiazides
- Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and/or aspirin
- Current or recent (within 3 months) participation in a clinical trial involving medication administration
- Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD
- Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders
- Any autoimmune disorder, inflammatory disorder, or medical condition that may interfere with safe study participation and/or study aims (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes)
- Any lifetime history of ulcer disease, gastritis, gastroenteritis, or gastrointestinal bleeding
- Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders
- Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms
- AST and ALT > four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% > the upper limit of the normal range
- Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12
- Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants
- Self-reported daily use of opioids (including prescribed)
- Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
- If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study
- Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
- Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and/or any antibiotic, prebiotic, or probiotic use within the last month
- Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol and nicotine
- Has below a 6th grade reading level
- Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity
Where in United States
- Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)Catonsville, United States
About the trial
What the trial wants to find out
This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.
The 2 groups in the trial
- DiclofenacExisting treatment, for comparison
Participants will take a single 100mg dose of diclofenac.
- PlaceboPlacebo, for comparison
Participants will take a single dose of placebo.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
- Record updated
- 27 March 2026